hit counter
AVEO Pharmaceuticals, Inc. (AVEO) Stock News Sentiment & Price - Sentifly
AVEO - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



AVEO Pharmaceuticals, Inc. (AVEO)

USA
Biotechnology
NASDAQ
AVEO Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AVEO Latest news
Business Wire
Neutral
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
2021-11-10 07:00

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in two upcoming virtual investor conferences: Stifel 2021 Healthcare Conference Date: Monday, November 15 Time: 1:20 p.m. Eastern Time 4th Annual Evercore ISI Healthconx Conference Date: Tuesday, November 30 Time: 12:35 p.m. Eastern Time A webcast of the fireside chats, or the subsequent archived record

Seeking Alpha
Neutral
AVEO Pharmaceuticals, Inc. (AVEO) CEO Michael Bailey on Q3 2021 Results - Earning Call Transcript
2021-11-08 19:56

AVEO Pharmaceuticals, Inc. (AVEO) CEO Michael Bailey on Q3 2021 Results - Earning Call Transcript

Zacks Investment Research
Positive
AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates
2021-11-08 19:09

AVEO (AVEO) delivered earnings and revenue surprises of 16.67% and 6.21%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Business Wire
Neutral
AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update
2021-11-08 16:05

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2021 and provided a business update. “During the third quarter, we continued to see strong commercial uptake for FOTIVDA®, further underscoring the significant unmet medical need that exists in the indicated treatment population. FOTIVDA has been well received by oncologists treating relapsed or refracto

Zacks Investment Research
Negative
Analysts Estimate AVEO Pharmaceuticals (AVEO) to Report a Decline in Earnings: What to Look Out for
2021-11-01 16:06

AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire
Neutral
AVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021
2021-11-01 07:00

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021. AVEO's management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, November 8, 2021, to discuss the financial results and provide a business update. The call can be accessed by dialing (844) 882-7841 (U.S. and Canada) or (574) 990-9828 (internationa

Seeking Alpha
Neutral
AVEO Pharmaceuticals: Sticking To The Plan
2021-10-29 08:52

KRBN invests in carbon credits, which have seen skyrocketing prices. The fund has significantly outperformed its peers since inception and seems set to continue to do so.

Business Wire
Neutral
AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by the U.S. FDA for the Treatment of Relapsed or Recurrent Head and Neck Squamous Cell Carcinoma
2021-09-20 07:00

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma (R/R HNSCC). Ficlatuzumab is AVEO's investigational potent humanized immunoglobulin G1 monoclonal antibody that targets hepatocyte growth factor. “The FDA's decisi

Business Wire
Neutral
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
2021-08-30 07:00

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that members of its senior management team will participate in two upcoming virtual investor conferences: H.C. Wainwright 23rd Annual Global Investment Conference Date: Monday, September 13 Time: 7:00 a.m. Eastern Time Baird 2021 Global Healthcare Conference Date: Tuesday, September 14 Time: 3:10 p.m. Eastern Time A live webcast of the Baird fireside chat can be accessed by visiting the investors section of the Company's webs

Seeking Alpha
Neutral
AVEO Pharmaceuticals, Inc. (AVEO) CEO Michael Bailey on Q2 2021 Results - Earnings Call Transcript
2021-08-05 21:20

AVEO Pharmaceuticals, Inc. (AVEO) CEO Michael Bailey on Q2 2021 Results - Earnings Call Transcript

Loading more news...